Advertisement

Topics

Cabazitaxel Not Superior to Docetaxel in Metastatic CRPC

02:42 EDT 8 Aug 2017 | Cancer Networks

Two different doses of cabazitaxel failed to show superiority with regard to overall survival over docetaxel as first-line treatment for patients with metastatic castration-resistant prostate cancer.

Original Article: Cabazitaxel Not Superior to Docetaxel in Metastatic CRPC

NEXT ARTICLE

More From BioPortfolio on "Cabazitaxel Not Superior to Docetaxel in Metastatic CRPC"

Quick Search
Advertisement